

Tulane center pioneers gene therapy treatment for severe hemophilia

Derek Amaya

damaya@tulane.edu

December 23, 2025 1:59 PM



Jacob Beard, 26 center, with the Louisiana Center for Bleeding and Clotting Disorders team after receiving the first gene therapy treatment for severe hemophilia A in Louisiana on Tuesday, Dec. 17, 2025, in Metairie.

The Louisiana Center for Bleeding and Clotting Disorders (LCBCD) became the first facility in the state to administer gene therapy for hemophilia A, treating Jacob Beard, 26, at its Metairie clinic in a milestone that marks a new era for bleeding disorder care in Louisiana. Located within the Tulane University School of Medicine, the center holds clinics at University Medical Center – New Orleans, Lakeside – Metairie, Villas at Angel Point – Lafayette, and Alexandria, Louisiana.

This groundbreaking therapy is a significant advancement in the treatment of hemophilia A, offering the potential for a life free from the risk of spontaneous bleeding and the need for frequent intravenous infusions of clotting factor.

The LCBCD continues to pioneer innovative treatments for bleeding disorders, reinforcing its mission as the state's only specialized clinic for both pediatric and adult patients with these conditions. Earlier in 2025, the LCBCD also successfully administered the first gene therapy for a patient with hemophilia B. These milestones represent a significant addition to previously available treatment options for patients with hemophilia.

The LCBCD's newly established specialized pharmacy facility, equipped with state-of-the-art technology and staffed by experts in bleeding disorder treatment, made this achievement possible.

"This milestone represents years of preparation and dedication from our entire team," said [Dr. Maissa Janbain](#), LCBCD director. "By successfully administering the first gene therapy treatment for hemophilia in Louisiana, we're not just making history – we're changing the future of bleeding disorder treatment in our state. This advance demonstrates our commitment to bringing innovative therapies to our patients."

Gene therapy for hemophilia works by delivering a functional copy of the gene to cells within the body, enabling the body to produce the deficient protein and reduce or eliminate the need for regular exogenous factor replacement therapy. This treatment option represents a significant step forward in comprehensive, innovative care for patients with bleeding disorders.

For more information about the Louisiana Center for Bleeding and Clotting Disorders and its services, please visit www.tulanelcbc.com or call (504) 988-5433.



Jacob Beard, 26, receives the first gene therapy infusion for severe hemophilia A in Louisiana from Amy Kinzie, clinic director at the Louisiana Center for Bleeding and Clotting Disorders, on Tuesday, Dec. 17, 2025, in Metairie.